Poor Ovarian Reserve
Conditions
Brief summary
Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor ovarian Reserve Patients
Detailed description
To study the effect of growth hormone as adjuvant treatment on the outcomes of ICSI trials in poor ovarian reserve patients.
Interventions
DRUG4 IU of recombinant GH (Somatotropin )
4 IU of recombinant GH
Sponsors
Beni-Suef University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
According to Bologna criteria (((at least two )))of the following features must be present: 1. Advanced maternal age (40years). 2. A previous poor ovarian response with 3 oocytes retrieved after conventional stimulation 3. An abnormal ovarian reserve test (ORT) * antral follicle count (AFC)\<7 or * anti-Müllerian hormone (AMH)\<1.1ng/ml.
Exclusion criteria
1. Any known contraindications to the approved fertility drugs. 2. Any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment) 4- Hydrosalpinx 5- Uterine malformations or abnormal uterine cavity. 6- Basal FSH more than 17 IU. 7- Abnormal karyotyping 8- Partner with severe male factor 9- Uncontrolled endocrinopathies: DM, hyperthyroidism, hypothyroidism.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pregnancy rate | ICSI trial (1month) | HCG positive |
Countries
Egypt
Contacts
Primary ContactSara A Salem, MD
Outcome results
None listed